Well yes, the time to get into PPHM was indeed H1/2012, or about two years ago. The prove of that are in the charts.
What happened next in Sept 21th 2012 is NOT the NORMAL course any more because we have been dealing with INTENTIONAL DOSE SWITCHING which is sabotage of our clinical trial NOT a planned corporate action or management decision of PPHM.
The PPS dropping from 5.40$ to 0.60$ in a few days is a NORMAL market response when on Sept 21th the public is warned not the rely on the results for investments and that a full investigation will be done.
The SALVAGING of the trial (finding out the sabotage, what happened and that the Sept 7th results were BETTER and not WORSE if the sabotage would not have occurred, has never been brought to the public with the same visibility as the Sept 21th announcement. We got the PIII approval and the Fast Track and a poorly timed PR (I could make a case why at PPHM's PR their should be a change made because I am seriously suspicious about those timings which support a PPS down or NEUTRAL impact of PPHM related good news. But OK it is up to BoD/Management to evaluate and take action if they concur with that assessment.).
And that is why it is said that this is the moment to buy PPHM. Actually we are privy of knowing the results of the trial while the mainstream retailer isn't aware of that or may possibly not even know that something happened. Most of them, luckily for us, don't even know PPHM exists.
One doesn't often get the chance of buying stock of small cap biotech's that have PII clinical trials with about 130% improvement on SOC and being Statistical Significant at the same time at the current prices. We actually thank that to the dose switching incident.
By the way, that will explain the resistance against attracting the attention of the, as we now know after the investigation, REAL results of the PII as announced on Sept 7th.
Why, because it is often said that small cap biotech have poor PIII reputations. And that is correct because they are mostly not statistical significant in their small sample PIIs (as Doctor Garnick said himself he has seldom seen PIIs to be stat sig as with Bavituximab).
So here with PPHM we run SUNRISE, the PIII of a PII that ended with 130+% improvement on SOC and Statistically Significant. As long as the bulk core of the public doesn't know that, all those in the known can smoothly fill there positions while keeping the PPS low.
How does Blackrock suddenly end up with so many PPHM shares (6 Milj +) without it having a positive impact on the PPS? Because they buy slow!
How can we move from 80Milj outstanding shares and 21% II to 180Milj outstanding shares and 17% II.
21% of 80 Milj = 16.8 Milj
17% of 180 Milj= 30.6 Milj
---------------------------
30.6-16.8= 13.8 Milj shares.
How come institutional bought 13.8 Milj shares of PPHM majorly starting in Q3/2012 and we didn't see it in the PPS?
Where are the many peaks over 3$ coming from that we saw since then? For ever sell there is a buy. How bought at 3$ ?
Why is it a general feeling that the LID is kept on this stock? That many say it is extremely under valuated for what sits in the pipeline? Why are we compared with the success stories from the parsed of companies with ONE drug or a SINGLE potential that are acquired by a BP while we have a Bavituximab pipeline for which, and I weight my words, their is by my knowledge no comparative on the complete market.
Why is the new contra-PPHM argumentation no longer based on Bavituximab doesn't work or will never be approaved, it is a placebo, etc but shifted to "it will take ages and they never may get their"?
It is ALL part of the same PPHM puzzle. To make big profits on PPHM the IIs, Funds and other deep pocket parties are not served with 500K to 2milj shares as we retailers. They load massively but don't want to do it while pushing there own price up. That is where black boxes come in.
News 
Market Data 
Discover 
AI
